Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Acute myeloid leukemia (AML) is generally regarded as a stem cell disease. In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38- population survives chemotherapy and is most probable the cause of minimal residual disease (MRD). The outgrowth of MRD causes relapse and MRD can therefore serve as a prognostic marker. The key role of leukemogenic CD34+CD38- cells led us to investigate whether they can be detected under MRD conditions. Various markers were identified to be aberrantly expressed on the CD34+CD38- population in AML and high-risk MDS samples at diagnosis, including C-type lectin-like molecule-1 and several lineage markers/marker-combinations. Fluorescent in situ hybridization analysis revealed that marker-positive cells were indeed of malignant origin. The markers were neither expressed on normal CD34+CD38- cells in steady-state bone marrow (BM) nor in BM after chemotherapy. We found that these markers were indeed expressed in part of the patients on malignant CD34+CD38- cells in complete remission, indicating the presence of malignant CD34+CD38- cells. Thus, by identifying residual malignant CD34+CD38- cells after chemotherapy, MRD detection at the stem cell level turned out to be possible. This might facilitate characterization of these chemotherapy-resistant leukemogenic cells, thereby being of help to identify new targets for therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AML leukemia initiating cells frequently have surface-phenotype features of lineage-commitment (CD34+38+, CLL-1+, CD71+, CD90−, c-Kit-)(42–52).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [46]
Citations
Cites
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Jordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Cozzio, A., Passegué, E., Ayton, P. M., Karsunky, H., Cleary, M. L., & Weissman, I. L. (2003) · Genes & Development · doi:10.1101/gad.1143403 · Cited by 663
van Rhenen, A., Feller, N., Kelder, A., Westra, A. H., Rombouts, E., Zweegman, S., van der Pol, M. A., Waisfisz, Q., Ossenkoppele, G. J., & Schuurhuis, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0468 · Cited by 375 · cited 1×
“We recently described that C-type lectin-like molecule-1 (CLL-1) is present on AML CD34þCD38 cells in the majority of patients and absent on CD34þCD38 cells in normal BM (NBM), which makes it a suitable stem cell marker (van Rhenen et al., Blood (2005) 106, 6a abstract).”
BackgroundSelf-citationSan Miguel, J. F., Vidriales, M. B., López-Berges, C., Dı́az-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M. J., Pérez, J. J., González, M., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1746 · Cited by 335
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
Wulf, G. G., Wang, R.-Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M. K., Andreeff, M., & Goodell, M. A. (2001) · Blood · doi:10.1182/blood.v98.4.1166 · Cited by 326
Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3948 · Cited by 275
Cited by
Terwijn, M., van Putten, W. L. J., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9628 · Cited by 442
Self-citationvan Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., Walsum, M. S.-V., Zweegman, S., Ossenkoppele, G. J., & Jan Schuurhuis, G. (2007) · Blood · doi:10.1182/blood-2007-03-083048 · Cited by 439
“Age at diagnosis, y, mean (range) 55 (16-79)”
Self-citationCoexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 336
Towards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., & Majeti, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100551108 · Cited by 311
Hedgehog Signaling in the Maintenance of Cancer Stem Cells
Cochrane, C., Szczepny, A., Watkins, D., & Cain, J. (2015) · Cancers · doi:10.3390/cancers7030851 · Cited by 271
Buccisano, F., Maurillo, L., Del Principe, M. I., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S., & Venditti, A. (2012) · Blood · doi:10.1182/blood-2011-08-363291 · Cited by 256
“Therefore, the concept of LAIP expression is something that applies even to LSC on which aberrant over-expression of CD47,(95) CD123, CD44 has been described.(94) Among markers of LCS aberrancy, C-type lectin-like molecule-1 (CLL-1) promises to be one of the most appealing since its expression is lacking on normal ste…”
BackgroundT-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Daver, N., Alotaibi, A. S., Bücklein, V., & Subklewe, M. (2021) · Leukemia · doi:10.1038/s41375-021-01253-x · Cited by 249
Measurable residual disease testing in acute myeloid leukaemia
Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017) · Leukemia · doi:10.1038/leu.2017.113 · Cited by 235
Self-citationLeukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Terwijn, M., Zeijlemaker, W., Kelder, A., Rutten, A. P., Snel, A. N., Scholten, W. J., Pabst, T., Verhoef, G., Löwenberg, B., Zweegman, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107587 · Cited by 215
Self-citationTettamanti, S., Marin, V., Pizzitola, I., Magnani, C. F., Giordano Attianese, G. M. P., Cribioli, E., Maltese, F., Galimberti, S., Lopez, A. F., Biondi, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12282 · Cited by 211
“…makes CD123 an interesting target molecule is the differential expression pattern, being overexpressed by the AML population (Biagi et al, 2007; Jin et al, 2009; Brentjens et al, 2010), and at the same time poorly expressed on normal HSPCs (Gal et al, 2006; van Rhenen et al, 2007; Jin et al, 2009).”
BackgroundCAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Wang, J., Chen, S., Xiao, W., Li, W., Wang, L., Yang, S., Wang, W., Xu, L., Liao, S., Liu, W., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0553-5 · Cited by 201
Zhou, Y., Othus, M., Araki, D., Wood, B. L., Radich, J. P., Halpern, A. B., Mielcarek, M., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Leukemia · doi:10.1038/leu.2016.46 · Cited by 190
Minimal residual disease in acute myeloid leukaemia
Hourigan, C. S., & Karp, J. E. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.100 · Cited by 180
Tashiro, H., Sauer, T., Shum, T., Parikh, K., Mamonkin, M., Omer, B., Rouce, R. H., Lulla, P., Rooney, C. M., Gottschalk, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.024 · Cited by 160
Cancer stem cells and cancer therapy
Soltanian, S., & Matin, M. M. (2011) · Tumor Biology · doi:10.1007/s13277-011-0155-8 · Cited by 159
“PTEN deficiency caused an initial expansion of normal HSCs due to their cycling, followed by their exhaustion.”
BackgroundInfluentialvan der Velden, V. H. J., van der Sluijs‐Gelling, A. J., Gibson, B. E. S., Marvelde, J. G. T., Hoogeveen, P. G., Hop, W. C. J., Wheatley, K., Bierings, M., Schuurhuis, G. J., de Graaf, S. S. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.153 · Cited by 143
Self-citationCraddock, C., Quek, L. S., Goardon, N., Freeman, S. D., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D. J., Ivey, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.312 · Cited by 154
Right on target: eradicating leukemic stem cells
Krause, D. S., & Etten, R. A. V. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.003 · Cited by 164
Zeijlemaker, W., Kelder, A., Oussoren-Brockhoff, Y. J. M., Scholten, W. J., Snel, A. N., Veldhuizen, D., Cloos, J. J., Ossenkoppele, G. J., & Schuurhuis, G. J. (2015) · Leukemia · doi:10.1038/leu.2015.252 · Cited by 144
Self-citationAddiction of t(8;21) and inv(16) Acute Myeloid Leukemia to Native RUNX1
Ben-Ami, O., Friedman, D., Leshkowitz, D., Goldenberg, D., Orlovsky, K., Pencovich, N., Lotem, J., Tanay, A., & Groner, Y. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.020 · Cited by 132
Leukemic stem cells: identification and clinical application
Hanekamp, D., Cloos, J. J., & Schuurhuis, G. J. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2221-5 · Cited by 145
Self-citationPollyea, D. A., Gutman, J. A., Gore, L., Smith, C. A., & Jordan, C. T. (2014) · Haematologica · doi:10.3324/haematol.2013.085209 · Cited by 133
Targeting CLL-1 for acute myeloid leukemia therapy
Ma, H., Iyer, S. P., Parmar, S., & Gong, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0726-5 · Cited by 114
Behbehani, G. K., Samusik, N., Bjornson, Z. B., Fantl, W. J., Medeiros, B. C., & Nolan, G. P. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0298 · Cited by 105
“Previous studies of aberrant surface markers on AML LSCs yielded inconsistent results, which may stem from the incorrect assumption that all AML LSCs have a similar phenotype (5, 27).”
BackgroundResultde Leeuw, D. C., Denkers, F., Olthof, M. C., Rutten, A. P., Pouwels, W., Schuurhuis, G. J., Ossenkoppele, G. J., & Smit, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1733 · Cited by 107
Self-citationAcute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach
Wood, B. L. (2020) · Current Protocols in Cytometry · doi:10.1002/cpcy.73 · Cited by 101
“…subsets of leukemic cells having immunophenotypes similar to those of normal hematopoietic stem cells are common in AML and may be associated with properties such as self-renewal and resistance to chemotherapy, and thus are important to evaluate (van Rhenen et al., 2007; Zeijlemaker et al., 2019).”
BackgroundMoshaver, B., van Rhenen, A., Kelder, A., van der Pol, M. A., Terwijn, M., Bachas, C., Westra, A. H., Ossenkoppele, G. J., Zweegman, S., & Schuurhuis, G. J. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0861 · Cited by 109
“We used CLL-1 and IL-3 receptor α-chain CD123, previously reported to be leukemic stem cell markers [4, 14] and the lineage markers CD7, CD19 and CD56, used to define blast cell aberrancies suitable for immunophenotypic MRD detection [15] and staining of AML CD34+CD38- LSC [3].”
BackgroundMethodInfluentialSelf-citationNCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML
Sasca, D., Szybinski, J., Schüler, A., Shah, V., Heidelberger, J. B., Haehnel, P. S., Dolnik, A., Kriege, O., Fehr, E.-M., Gebhardt, W. H., et al. (2019) · Blood · doi:10.1182/blood-2018-12-889725 · Cited by 114
Negrotto, S., Ng, K. P., Jankowska, A. M., Bodo, J., Gopalan, B., Guinta, K., Mulloy, J. C., Hsi, E., Maciejewski, J., & Saunthararajah, Y. (2012) · Leukemia · doi:10.1038/leu.2011.207 · Cited by 90
Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia
Freeman, S. D., Jovanovic, J. V., & Grimwade, D. J. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.009 · Cited by 99
Tierens, A. M., Björklund, E., Siitonen, S. M., Marquart, H. V., Jürgensen, G. W., Pelliniemi, T., Forestier, E., Hasle, H., Jahnukainen, K., Lausen, B., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14093 · Cited by 89
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
Staudt, D. E., Murray, H. C., McLachlan, T., Alvaro, F., Enjeti, A. K., Verrills, N. M., & Dun, M. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103198 · Cited by 85
Ommen, H. B. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715614529 · Cited by 91
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
Sugita, M., Galetto, R., Zong, H., Ewing-Crystal, N. A., Trujillo-Alonso, V., Mencia-Trinchant, N., Yip, W., Filipe, S., Lebuhotel, C., Gouble, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29668-9 · Cited by 78
Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity
Arnone, M., Konantz, M., Hanns, P., Stanger, A. M. P., Bertels, S., Godavarthy, P. S., Christopeit, M., & Lengerke, C. (2020) · Cancers · doi:10.3390/cancers12123742 · Cited by 90
Schuurhuis, G. J., Meel, M. H., Wouters, F., Min, L. A., Terwijn, M., de Jonge, N., Kelder, A., Snel, A. N., Zweegman, S., Ossenkoppele, G. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078897 · Cited by 78
Self-citationCD 45 RA , a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia
Kersten, B., Valkering, M., Wouters, R., van Amerongen, R. A., Hanekamp, D., Kwidama, Z. J., Valk, P. J. M., Ossenkoppele, G. J., Zeijlemaker, W., Kaspers, G. J. L., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13941 · Cited by 70
Self-citationNg, K. P., Ebrahem, Q., Negrotto, S., Mahfouz, R. Z., Link, K. A., Hu, Z., Gu, X., Advani, A., Kalaycio, M., Sobecks, R., et al. (2011) · Leukemia · doi:10.1038/leu.2011.159 · Cited by 68
Chen, Y., Cortes, J. E., Estrov, Z. E., Faderl, S. H., Qiao, W., Abruzzo, L. V., Garcia‐Manero, G., Pierce, S. A., Huang, X., Kebriaei, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2873 · Cited by 65
“01%) is likely to be improved by 6 to 8 color flow technology(35) and by the characterization of markers such as CLL-1 that appear to differentiate between leukemic and normal stem cells.(37-38) The observation that persistent cytogenetic abnormalities at CR after induction has an independent prognostic value in AML s…”
BackgroundLarsen, H. Ø., Roug, A. S., Just, T., Brown, G. D., & Hokland, P. (2011) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20614 · Cited by 63
Leukemia stem cells in 2010: Current understanding and future directions
Becker, M. W., & Jordan, C. T. (2011) · Blood Reviews · doi:10.1016/j.blre.2010.11.001 · Cited by 74
Leukemia cells induce changes in human bone marrow stromal cells
Civini, S., Jin, P., Ren, J., Sabatino, M., Castiello, L., Jin, J., Wang, H., Zhao, Y., Marincola, F. M., & Stroncek, D. F. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-298 · Cited by 68
Acute myeloid leukemia stem cells: seek and destroy
Roboz, G. J., & Guzmán, M. L. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.53 · Cited by 74
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia
Morsink, L. M., Walter, R. B., & Ossenkoppele, G. J. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.10.003 · Cited by 62
Self-citationLi, S., Xu, L., Wang, Y., Zhang, X., Chen, H., Chen, Y., Wang, F., Han, W., Sun, Y., Yan, C.-H., et al. (2022) · Blood · doi:10.1182/blood.2021014604 · Cited by 60
Testa, U. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1118-7 · Cited by 71
Emerging CAR T Cell Strategies for the Treatment of AML
Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L., & Hui, S. K. (2022) · Cancers · doi:10.3390/cancers14051241 · Cited by 64
Hwang, K., Park, C., Jang, S., Chi, H., Kim, D., Lee, J., Lee, J., Lee, K. H., Im, H., & Seo, J. J. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1501-7 · Cited by 58
“LSCs could also be responsible for relapse by persisting as minimal residual disease (MRD) after chemotherapy [4, 22].”
BackgroundHoang, V. T., Buss, E. C., Wang, W., Hoffmann, I., Raffel, S., Zepeda‐Moreno, A., Baran, N., Wuchter, P., Eckstein, V., Trumpp, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29410 · Cited by 58
Xu, J., Jorgensen, J. L., & Wang, S. A. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.07.004 · Cited by 57
Williams, B. A., Law, A., Hunyadkürti, J., Désilets, S., Leyton, J. V., & Keating, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081261 · Cited by 62
Unveiling the potential of CLL-1: a promising target for AML therapy
Samarkhazan, H. S., Zehtabcheh, S., Seraji, H. R., Beqaj, S., Tayefeh, S., Mohammadi, M. H., & Aghaei, M. (2025) · Biomarker Research · doi:10.1186/s40364-025-00738-6 · Cited by 55
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Vyas, P., Appelbaum, F. R., & Craddock, C. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.026 · Cited by 56
Saunthararajah, Y., Triozzi, P., Rini, B., Singh, A., Radivoyevitch, T., Sekeres, M., Advani, A., Tiu, R., Reu, F., Kalaycio, M., et al. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.011 · Cited by 53
Roboz, G. J., Ritchie, E. K., Dault, Y., Lam, L., Marshall, D. C., Cruz, N. M., Hsu, H.-T., Hassane, D. C., Christos, P. J., Ippoliti, C. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183418 · Cited by 54
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
Marvin‐Peek, J., Savani, B. N., Oluwole, O. O., & Dholaria, B. (2022) · Cancers · doi:10.3390/cancers14030497 · Cited by 52
“CAR T-cells against the receptor show activity against monocyte AML cells with sparing of healthy HSCs [127].”
BackgroundInfluentialRoug, A. S., Larsen, H. Ø., Nederby, L., Just, T., Brown, G. D., Nyvold, C. G., Ommen, H. B., & Hokland, P. (2013) · British Journal of Haematology · doi:10.1111/bjh.12614 · Cited by 51
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia
Wang, M., Yang, C., Zhang, L., & Schaar, D. G. (2017) · Stem Cells International · doi:10.1155/2017/6962379 · Cited by 55
Soerensen, J. F., Aggerholm, A., Kerndrup, G. B., Hansen, M. H., Ewald, I. K. L., Bill, M., Ebbesen, L. H., Rosenberg, C. A., Hokland, P., Ludvigsen, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001157 · Cited by 51
Czyż, A., & Nagler, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215362 · Cited by 52
Bill, M., Niekerk, P. B. V. K., Woll, P. S., Herborg, L. L., Roug, A. S., Hokland, P., & Nederby, L. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13519 · Cited by 52
Understanding stem cells and its pivotal role in regenerative medicine
Sarkar, A., Saha, S., Paul, A., Maji, A., Roy, P., & Maity, T. K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119270 · Cited by 55
Jawad, M., Seedhouse, C., Mony, U., Grundy, M. A., Russell, N. H., & Pallis, M. (2009) · Leukemia · doi:10.1038/leu.2009.199 · Cited by 45
Hanekamp, D., Denys, B., Kaspers, G. J. L., Marvelde, J. G. T., Schuurhuis, G. J., de Haas, V., Moerloose, B. D., de Bont, E. S., Zwaan, C. M., de Jong, A., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14991 · Cited by 44
Self-citationMony, U., Jawad, M., Seedhouse, C., Russell, N. H., & Pallis, M. (2008) · Leukemia · doi:10.1038/leu.2008.125 · Cited by 43
Methods of Detection of Measurable Residual Disease in AML
Zhou, Y., & Wood, B. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0419-5 · Cited by 41
Pleșa, A., Dumontet, C., Mattei, E., Tagoug, I., Hayette, S., Sujobert, P., Tigaud, I., Pagès, M. P., Chelghoum, Y., Baracco, F., et al. (2017) · World Journal of Stem Cells · doi:10.4252/wjsc.v9.i12.227 · Cited by 45
Chávez‐González, A., Dorantes-Acosta, E. M., Moreno-Lorenzana, D., Alvarado‐Moreno, J. A., Arriaga‐Pizano, L., & Mayani, H. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.04.001 · Cited by 37
A Cross Entropy Test Allows Quantitative Statistical Comparison of t-SNE and UMAP Representations
Roca, C. P., Burton, O. T., Neumann, J., Tareen, S. H. K., Whyte, C. E., Gergelits, V., Veiga, R., Humblet‐Baron, S., & Liston, A. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100390 · Cited by 48
“Broader use of a cross entropy test approach within the diagnostics field may provide higher sensitivity to the detection of atypical immunological disorders or hematological malignancies, as the integrated statistical would incorporate the detection of both aberrant marker expression and the development of rare/unusu…”
BackgroundBradbury, C. A., Houlton, A. E., Akiki, S. J., Gregg, R., Rindl, M., Khan, J., Ward, J., Khan, N., Griffiths, M., Nagra, S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.327 · Cited by 36
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
Mosna, F., Capelli, D., & Gottardi, M. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6060057 · Cited by 37
Mitchell, K., & Steidl, U. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036251 · Cited by 40
Janssen, J. J. W. M., Deenik, W., Smolders, K., van Kuijk, B. J., Pouwels, W., Kelder, A., Cornelissen, J. J., Schuurhuis, G. J., & Ossenkoppele, G. J. (2011) · Leukemia · doi:10.1038/leu.2011.347 · Cited by 34
Self-citationNew molecular concepts and targets in acute myeloid leukemia
Buzzai, M., & Licht, J. D. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f3ded0 · Cited by 36
Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome
Bill, M., Nederby, L., Kjeldsen, E., Kerndrup, G. B., Brown, G. D., Hokland, P., & Roug, A. S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14270 · Cited by 36
“Furthermore, CLEC12A has been proposed as a possible marker for LSC as it can be found on CD34+CD38 cells in CD34-positive AML, but is completely absent on the CD34+CD38 compartment in normal donors and in regenerating BM (van Rhenen et al, 2007a).”
BackgroundMethodInfluentialCairo, M. S., Jordan, C. T., Maley, C. C., Chao, C., Melnick, A. M., Armstrong, S. A., Shlomchik, W. D., Molldrem, J., Ferrone, S., Mackall, C. L., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.03.002 · Cited by 35
Identifying leukemia stem cells – Is it feasible and does it matter?
Lutz, C., Hoang, V. T., Buss, E. C., & Ho, A. D. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.014 · Cited by 30
Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry
Fuda, F. S., & Chen, W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0479-1 · Cited by 30
Expression of embryonic stem cell markers in acute myeloid leukemia
Picot, T., Aanei, C. M., Fayard, A., Flandrin‐Gresta, P., Tondeur, S., Gouttenoire, M., Tavernier, E., Wattel, E., Guyotat, D., & Campos, L. (2017) · Tumor Biology · doi:10.1177/1010428317716629 · Cited by 30
“Total ribonucleic acid (RNA) from cell lines, 16 leukemic samples (4 with t(8;21), 4 with inv(16), 4 with t(15;17), and 4 with normal karyotype) and 4 normal bone marrow mononuclear cells (MNCs), was extracted using a chloroform phenol extraction method.”
BackgroundMethodGasparetto, M., Pei, S., Minhajuddin, M., Khan, N., Pollyea, D. A., Myers, J. R., Ashton, J. M., Becker, M. W., Vasiliou, V., Humphries, R. K., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159053 · Cited by 31
Marvin, J., Swaminathan, S., Kraker, G., Chadburn, A., Jacobberger, J. W., & Goolsby, C. L. (2011) · Blood · doi:10.1182/blood-2010-10-316026 · Cited by 26
CD45dimCD34+CD38−CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia
Heo, S., Noh, E., Ju, L. J., Sung, J. Y., Jeong, Y. K., Cheon, J., Koh, S. J., Min, Y. J., Choi, Y., & Jo, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-06760-1 · Cited by 29
Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation
Ng, K. P., Hu, Z., Ebrahem, Q., Negrotto, S., Lausen, J., & Saunthararajah, Y. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.41 · Cited by 28
Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance
Hoang, V. T., Zepeda‐Moreno, A., & Ho, A. D. (2012) · Biotechnology Journal · doi:10.1002/biot.201100350 · Cited by 27
CD123 as a Therapeutic Target Against Malignant Stem Cells
Sugita, M., & Guzmán, M. L. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.01.004 · Cited by 25
Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells
van der Werf, I. M., Mondala, P. K., Steel, K., Balaian, L., Ladel, L., Mason, C. N., Diep, R. H., Pham, J., Cloos, J. J., Kaspers, G. J. L., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100962 · Cited by 32
“Thesephenotypicmarkers include CD47, CLL-1 (also known as CLEC12a), TIM3, CD7, CD123, CD96, CD33, and CD44.”
ResultSurvival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients
Zahran, A. M., Aly, S. S., Rayan, A., El‐Badawy, O., Abdelfattah, M., Ali, A., ElBadre, H. M., & Hetta, . F. (2018) · Oncotarget · doi:10.18632/oncotarget.26118 · Cited by 24
Can immunotherapy specifically target acute myeloid leukemic stem cells?
Snauwaert, S., Vandekerckhove, B., & Kerre, T. C. C. (2013) · OncoImmunology · doi:10.4161/onci.22943 · Cited by 26
Principe, M. I. D. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.052 · Cited by 24
Targeting Myeloid Leukemia Stem Cells
Jordan, C. T. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000914 · Cited by 25
Wang, L., Gao, L., Xu, S., Gong, S., Chen, L., Lü, S., Chen, J., Qiu, H., Xu, X., Ni, X., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-85 · Cited by 23
Huang, X., Li, D., Li, T., ZHAO, B., & Chen, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3189 · Cited by 23
“CD44 is also considered to be one of the particular markers that mediate efficient homing and engraftment of LSC in AML (34-36).”
The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia
Buccisano, F., Hourigan, C. S., & Walter, R. B. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0420-z · Cited by 27
Tan, Y., Wu, Q., & Zhou, F. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102993 · Cited by 22
Role of epigenetic modulation in cancer stem cell fate
Deshmukh, A. P., Binju, M., Arfuso, F., Newsholme, P., & Dharmarajan, A. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.07.003 · Cited by 24
“Recently, methylation of the promoter of genes involved in the Wnt signaling pathway has been identified in the case of breast cancer (Ai et al., 2006; Suzuki et al., 2008; Veeck et al., 2006; Virmani et al., 2001).”
BackgroundUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
Stahl, M. F., Kim, T. K., & Zeidan, A. M. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i10.316 · Cited by 20
Moritz, J. M., Schwab, A., Reinisch, A., Zebisch, A., Sill, H., & Wölfler, A. (2024) · Biomedicines · doi:10.3390/biomedicines12030599 · Cited by 25
Shapira, S., Raanani, P., Samara, A., Nagler, A., Lubin, I., Arber, N., & Granot, G. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.10.010 · Cited by 22
Wouters, R., Cucchi, D. G. J., Kaspers, G. J. L., Schuurhuis, G. J., & Cloos, J. J. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.959921 · Cited by 20
Self-citation
Metadata
- Authors
- van Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A. W. M., Zweegman, S., Ossenkoppele, G. J., & Schuurhuis, G. J.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Schuurhuis, G J
- Venue
- Leukemia
- Published
- 2007-05-24
- Volume
- 21
- Issue
- 8
- Pages
- 1700-1707
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2071293034
- Cited by
- 193
- References
- 20
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 12 · 2021: 9 · 2020: 12 · 2019: 16 · 2018: 14 · 2017: 17 · 2016: 9 · 2015: 9 · 2014: 15 · 2013: 15 · 2012: 8
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, leukemia stem cells, CD34+CD38- cells, minimal residual disease, complete remission, high-risk myelodysplastic syndrome, chemoresistance, prognostic factors, bone marrow-derived stem cells
- MeSH terms
- Acute Disease, Adolescent, Adult, Aged, Bone Marrow, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Leukemia, Myeloid, Male, Middle Aged, Prognosis, Remission Induction, Risk Factors, Biomarkers, Tumor, Neoplastic Stem Cells, Survival Rate, Immunophenotyping, In Situ Hybridization, Fluorescence, Neoplasm, Residual, Antigens, CD34, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.